Researchers at the Indiana University School of Medicine have developed a more accurate and cost-effective method for predicting childhood asthma by using a new passive digital marker based on routinely collected electronic health record (EHR) data. The study, published in eClinicalMedicine, represents a significant step forward in early asthma detection, aiming to reduce delays in diagnosis and improve long-term outcomes for children at high risk for developing the disease.
Advertisement
Researchers identified 4 genes tied to propionate metabolism to predict head and neck cancer risk and survival.
AI-enhanced HER2 scoring improves accuracy and may expand patient access to HER2-targeted therapies in breast cancer care.
Nutritional epigenetics may help prevent autism and ADHD via maternal diet changes.
A review and meta-analysis revealed an association between crescents and worsened renal outcomes in patients with IgAN.
Excess brain iron in Down syndrome linked to oxidative damage and early-onset Alzheimer’s, new study finds.
Psychedelics may ease depression and PTSD by reducing brain inflammation and restoring vascular and immune balance.
Dr. Kelly McCann reviews sequencing and emerging therapies in HR-positive, HER2-negative metastatic breast cancer.
Dr. Kelly McCann of UCLA details HER2-positive breast cancer sequencing and toxicity management.
DocWire Content Partners
Powered by DocWire News
The Latest From GI Oncology Now
Suvemcitug, envafolimab, and FOLFIRI may serve as a new second-line treatment option for cold tumors.
KRASG12C inhibitors can have reduced efficacy in patients with alterations in KRAS, EGFR, and other genes.
Complete responders with HCC have prolonged survival and durable disease control even after therapy has been discontinued.
The primary objective of median PFS was significantly longer for patients treated with 177Lu-edotreotide.
The safety profile of the combination was consistent with known profiles, and no new safety findings were observed.
Older patients in their 70s with extrahepatic CCA have a higher rate of choledocholithiasis.
The Latest From Heme Today
The phase 3 VERONA trial, which compared this combination with placebo plus azacitidine, observed no new safety signals.
Dr. John Gansner and Dr. Martina H. Slingsby argue this new agent can provide benefit across all bleeding disorders.
Heme Today spoke with Ulrike Reiss, MD, and Andrew Davidoff, MD, of the trial's investigator team.
Gene therapy is reshaping sickle cell care, raising awareness and advancing treatments beyond the lab.
ASH warns NIH cuts would jeopardize blood disorder care and halt key progress in hematology research.